Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myeloid, Acute 18Hematologic Neoplasms 15Myelodysplastic Syndromes 14Leukemia, Lymphocytic, Chronic, B-Cell 9Multiple Myeloma 7Lymphoma, Non-Hodgkin 6Lymphoma 6Hodgkin Disease 6Leukemia 5Recurrence 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Large B-Cell, Diffuse 4Myeloproliferative Disorders 3Lymphoma, T-Cell 3Lymphoma, Large-Cell, Anaplastic 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Turcot syndrome 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Primary Myelofibrosis 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Neuroblastoma 2Mycosis Fungoides 2Melanoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Follicular 2Lymphoma, Extranodal NK-T-Cell 2

Interventions

Azacitidine 5venetoclax 4Specimen Handling 3Nivolumab 2regorafenib 1midostaurin 1iadademstat 1fludarabine phosphate 1fludarabine 1decitabine and cedazuridine drug combination 1Whole-Body Irradiation 1Vorinostat 1Thiotepa 1Tacrolimus 1Methotrexate 1Lenalidomide 1Injections 1Decitabine 1Cytarabine 1Cyclophosphamide 1Busulfan 1Bone Marrow Transplantation 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
GATA2 Deficiency × Nivolumab × Other hematologic neoplasm × Clear all
NCT03092674 2025-01-16

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 2/3 Completed
76 enrolled 16 charts
MyeloidOther hematologic neoplasm

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04361058 2023-12-05

Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide

SCRI Development Innovations, LLC

Phase 1 Withdrawn
MyeloidOther hematologic neoplasm

GATA2 Deficiency, Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡